Maribavir: A promising new antiherpes therapeutic agent

New Concepts of Antiviral Therapy

Volumn , Issue , 2006, Pages 309-336

  Biron, Karen K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919876172     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-31047-3_11     Document Type: Chapter

References (98)

1. Cytovene-IV (ganciclovir sodium for intravenous infusion only) and Cytovene (ganciclovir capsules for oral administration only), package insert. Roche Laboratories, Inc. June 2000.
2. Foscavir (foscarnet injection) package insert. Astra Zeneca, Inc. June 2000.
3. Vistide (cidofovir injection) package insert. Gilead Sciences, Inc. September 1996.
4. Abenes, G., Lee, M., Haghjoo, E., Tong, T., Zhan, X. and Liu, F., 2001, Murine cytomegalovirus open reading frame M27 plays an important role in growth and virulence in mice. J. Virol. 75:1697-1707.
5. Baek, M C., Krosky, P. M., He, Z. and Coen, D. M., 2002, Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P+5 position. J. Biol. Chem. 277:29593-29599.
6. Balfour, H. H., Jr., Chace, B. A., Stapleton, J. T., Simmons, R. L. and Fryd, D. S., 1989, A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N. Engl. J. Med. 320:1381-1387.
7. Biron, K. K., Harvey, R. J., Chamberlain, S. C., Good, S. S., Smith, A. A., III, Davis, M. G., Talarico, C. L., Miller, W. H., Ferris, R., Dornsife, R. E., Stanat, S. C., Drach, J. C., Townsend, L. B. and Koszalka, G. W., 2002, Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
8. Bogner, E., 2002, Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:115-127.
9. Cepok, S., Zhou, D., Srivastava, R., Nessler, S., Stei, S., Bussow, K., Sommer, N. and Hemmer, B., 2005, Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest 115:1352-1360.
10. Chan, J. H., Chamberlain, S. D., Biron, K. K., Davis, M. G., Harvey, R. J., Selleseth, D. W., Dornsife, R. E., Dark, E H., Frick, L. W., Townsend, L B., Drach, J C. and Koszalka, G. W., 2000, Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5, 6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94). Nucleosides Nucleotides Nucleic Acids 19:101-123.
11. Chee, M. S., Lawrence, G. L. and Barrell, B. G., 1989, Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Virol. 70(Pt 5):1151-1160.
12. Chen, C J., Lin, K. H., Lin, S. C., Tsai, W. C., Yen, J. H., Chang, S. J., Lu, S. N. and Liu, H. W., 2005, High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J. Rheumatol. 32:44-47.
13. Chen, M. R., Chang, S. J., Huang, H. and Chen, J Y., 2000, A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J. Virol. 74:3093-3104.
14. Chou, S., 1999, Antiviral drug resistance in human cytomegalovirus. Transpl. Infect. Dis. 1:105-114.
15. Chou, S., Lurain, N. S., Thompson, K. D., Miner, R. C. and Drew, W. L., 2003, Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39.
16. Chou, S., Marousek, G. I., Senters, A. E., Davis, M. G. and Biron, K. K., 2004, Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78:7124-7130.
17. Chou, S. W., 2001,. Cytomegalovirus drug resistance and clinical implications. Transpl. Infect. Dis. 3 Suppl 2:20-24.
18. Coulter, L. J., Moss, H. W., Lang, J. and McGeoch, D. J., 1993, A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted. J. Gen. Virol. 74(Pt 3):387-395.
19. Crumpacker, C. S., 1996, Ganciclovir. N. Engl. J. Med. 335:721-729.
20. Cvetkovic, R. S. and Wellington, K., 2005, Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65:859-878.
21. Dittmer, A., Drach, J. C., Townsend, L. B., Fischer, A. and Bogner, E., 2005, Interaction of the putative HCMV portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J. Virol. 79: in press.
22. Elion, G. B., Furman, P. A., Fyfe, J. A., De Miranda, P., Beauchamp, L. and Schaeffer, H. J., 1977, Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U. S. A 74:5716-5720.
23. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
24. Evers, D. L., Komazin, G., Ptak, R. G., Shin, D., Emmer, B. T., Townsend, L. B. and Drach, J. C., 2004, Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob. Agents Chemother. 48:3918-3927.
25. Evers, D. L., Komazin, G., Shin, D., Hwang, D. D., Townsend, L. B. and Drach, J. C., 2002, Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral Res. 56:61-72.
26. Gershburg, E. and Pagano, J. S., 2002, Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J. Virol. 76:998-1003.
27. Gross, A. J., Hochberg, D., Rand, W. M. and Thorley-Lawson, D. A., 2005, EBV and systemic lupus erythematosus: a new perspective. J. Immunol. 174:6599-6607.
28. Hanks, S. K., Quinn, A. M. and Hunter, T., 1988, The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
29. He, Z., He, Y. S., Kim, Y., Chu, L., Ohmstede, C., Biron, K. K. and Coen, D. M., 1997, The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 71:405-411.
30. Hendrix C., Kuppermann, B. D., Dunn J. P., Wang L. H., Starns E., Snowden B. W., Hamzeh F. and Wire M. B., 2000, A phase I trial to evaluate the ocular (intravitreal) penetration of 1263W94 after multiple dose, oral administration in AIDS patients with CMV retinitis. 40th ICAAC.
31. Hodson, E. M., Jones, C. A., Webster, A. C., Strippoli, G. F., Barclay, P. G., Kable, K., Vimalachandra, D. and Craig, J. C., 2005, Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365:2105-2115.
32. Jacobson, M. A., 1992, Review of the toxicities of foscarnet. J. Acquir. Immune. Defic. Syndr. 5 Suppl 1:S11-S17.
33. James, J. A., Neas, B. R., Moser, K. L., Hall, T., Bruner, G. R., Sestak, A. L. and Harley, J. B., 2001, Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 44:1122-1126.
34. Kato, K., Kawaguchi, Y., Tanaka, M., Igarashi, M., Yokoyama, A., Matsuda, G., Kanamori, M., Nakajima, K., Nishimura, Y., Shimojima, M., Phung, H. T., Takahashi, E. and Hirai, K., 2001, Epstein-Barr virus-encoded protein kinase BGLF4 mediates hyperphosphorylation of cellular elongation factor 1delta (EF-1delta): EF-1delta is universally modified by conserved protein kinases of herpesviruses in mammalian cells. J. Gen. Virol. 82:1457-1463.
35. Kawaguchi, Y. and Kato, K., 2003, Protein kinases conserved in herpesviruses potentially share a function mimicking the cellular protein kinase cdc2. Rev. Med. Virol. 13:331-340.
36. Kenyon, T. K., Lynch, J., Hay, J., Ruyechan, W. and Grose, C., 2001, Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphortransferase and two viral substrates, ORF62 and ORF63. J. Virol. 75:8854-8858.
37. Kern, E. R., Hartline, C. B., Rybak, R. J., Drach, J. C., Townsend, L. B., Biron, K. K. and Bidanset, D. J., 2004, Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob. Agents Chemother. 48:1749-1755.
38. Komazin, G., Ptak, R. G., Emmer, B. T., Townsend, L. B. and Drach, J. C., 2003, Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J. Virol. 77:11499-11506.
39. Komazin, G., Townsend, L. B. and Drach, J. C., 2004, Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides. J. Virol. 78:710-715.
40. Koszalka, G. W., Johnson, N. W., Good, S. S., Boyd, L., Chamberlain, S. C., Townsend, L. B., Drach, J. C. and Biron, K. K., 2002, Pre-clinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46:2373-2380.
41. Krosky, P. M., Baek, M. C. and Coen, D. M., 2003a, The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
42. Krosky, P. M., Baek, M. C., Jahng, W. J., Barrera, I., Harvey, R. J., Biron, K. K., Coen, D. M., and Sethna, P. B. 2003b. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77:7720-7727.
43. Krosky, P. M., Underwood, M. R., Turk, S. R., Feng, K. W., Jain, R. K., Ptak, R. G., Westerman, A. C., Biron, K. K., Townsend, L. B. and Drach, J. C., 1998, Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
44. Lalezari, J. P., Aberg, J. A., Wang, L. H., Wire, M. B., Miner, R., Snowden, W., Talarico, C. L., Shaw, S., Jacobson, M. A. and Drew, W. L., 2002, Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
45. Lalezari, J. P., Drew, W. L., Glutzer, E., James, C., Miner, D., Flaherty, J., Fisher, P. E., Cundy, K., Hannigan, J., and Martin, J. C. 1995. (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788-796.
46. Levin, L. I., Munger, K. L., Rubertone, M., Peck, C. A., Lennette, E. T., Spiegelman, D. and Ascherio, A., 2005, Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293:2496-2500.
47. Lowance, D., Neumayer, H. H., Legendre, C. M., Squifflet, J. P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., Crisp, A. and Lee, I. C., 1999, Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340:1462-1470.
48. Lu, H. and Thomas, S., 2004, Maribavir (ViroPharma). Curr. Opin. Investig. Drugs 5:898-906.
49. Lurain, N. S., Weinberg, A., Crumpacker, C. S. and Chou, S., 2001, Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother. 45:2775-2780.
50. Ma, J. D., Nafziger, A. N., Villano, S. A., Gaedigk, A. and Victory, J., 2005a, Effect of the anticytomegalovirus drug maribavir on the activities of cytochrome P450 (CYP) 1A2, 2C9, 2C19, 2D6, 3A, N-acetyltransferase-2, and xanthine oxidase as Assessed by the Modified Cooperstown 5+1 Drug Cocktail. 2005, American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual meeting in Orlando, Florida, Abstract PI-43.
51. Ma, J. D., Nafziger, A. N., Villano, S. A., Victory, J. and Bertino, J. S., 2005b, Single and multiple dose pharmacokinetics (PK) of maribavir (MB) in healthy adults. 2005 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual meeting in Orlando, Florida.
52. Marschall, M., Freitag, M., Suchy, P., Romaker, D., Kupfer, R., Hanke, M. and Stamminger, T., 2003, The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311:60-71.
53. McSharry, J. J., McDonough, A., Olson, B., Hallenberger, S., Reefschlaeger, J., Bender, W. and Drusano, G. L., 2001a, Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob. Agents Chemother. 45:2925-2927.
54. McSharry, J. J., McDonough, A., Olson, B., Talarico, C., Davis, M. and Biron, K. K., 2001b, Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin. Diagn. Lab Immunol. 8:1279-1281.
55. Mettenleiter, T. C., 2002, Herpesvirus assembly and egress. J. Virol. 76:1537-1547.
56. Michel, D., Kramer, S., Hohn, S., Schaarschmidt, P., Wunderlich, K. and Mertens, T., 1999, Amino acids of conserved kinase motifs of cytomegalovirus protein UL97 are essential for autophosphorylation. J. Virol. 73:8898-8901.
57. Michel, D. and Mertens, T., 2004, The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host. Biochim. Biophys. Acta 1697:169-180.
58. Michel, D., Pavic, I., Zimmermann, A., Haupt, E., Wunderlich, K., Heuschmid, M. and Mertens, T., 1996, The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 70:6340-6346.
59. Moffat, J. F., Zerboni, L., Sommer, M. H., Heineman, T. C., Cohen, J. I., Kaneshima, H. and Arvin, A. M., 1998, The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc. Natl. Acad. Sci. U. S. A 95:11969-11974.
60. Okano, M., 2003, The evolving therapeutic approaches for Epstein-Barr virus infection in immunocompetent and immunocompromised individuals. Curr. Drug Targets. Immune. Endocr. Metabol. Disord. 3:137-142.
61. Pagano, J. S., 1999, Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc. Assoc. Am. Physicians 111:573-580.
62. Parks, C. G., Cooper, G. S., Hudson, L. L., Dooley, M. A., Treadwell, E. L., St Clair, E. W., Gilkeson, G. S. and Pandey, J. P., 2005, Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyteassociated antigen 4 genotype. Arthritis Rheum. 52:1148-1159.
63. Perrot, S., Calvez, V., Escande, J. P., Dupin, N. and Marcelin, A. G., 2003, Prevalences of herpesviruses DNA sequences in salivary gland biopsies from primary and secondary Sjogren's syndrome using degenerated consensus PCR primers. J. Clin. Virol. 28:165-168.
64. Prichard, M. N., Gao, N., Jairath, S., Mulamba, G., Krosky, P., Coen, D. M., Parker, B. O. and Pari, G. S., 1999, A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:5663-5670.
65. Prichard, M. N., Hartline, C. B., Britt, W. J. and Kern, E. R., 2005, Maribavir induces the formation of tegument aggregates in cells infected with human cytomegalovirus Abstracts of the 18th International Conference on Antiviral Research. Barcelona, Spain, April 11-14, 2005. Antiviral Res 65:A27-108.
66. Purves, F. C., Ogle, W. O. and Roizman, B., 1993, Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. Proc. Natl. Acad. Sci. U. S. A 90:6701-6705.
67. Reddy, S. M., Cox, E., Iofin, I., Soong, W. and Cohen, J. I., 1998, Varicella-zoster virus (VZV) ORF32 encodes a phosphoprotein that is posttranslationally modified by the VZV ORF47 protein kinase. J. Virol. 72:8083-8088.
68. Resnick, L., Herbst, J. S., Ablashi, D., Atherton, S., Frank, B., Rosen, L. and Horwitz, S. N., 1988, Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 259:384-388.
69. Reusser, P., 2001, Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert. Opin. Investig. Drugs 10:1745-1753.
70. Roizman, B., 1996, Herpesviridae. In Herpesviridae (B. N. Fields, D. M. Knipe, and P. M. Howley, Eds.), pp. 2221-2230. Philadelphia.
71. Safrin, S., Cherrington, J. and Jaffe, H. S., 1999, Cidofovir. Review of current and potential clinical uses. Adv. Exp. Med. Biol. 458:111-120.
72. Selleseth, D. W., Talarico, C. L., Miller, T., Lutz, M. W., Biron, K. K. and Harvey, R. J., 2003, Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob. Agents Chemother. 47:1468-1471.
73. Smith, R. F. and Smith, T. F., 1989, Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J. Virol. 63:450-455.
74. Springer, K. L. and Weinberg, A., 2004, Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J. Antimicrob. Chemother. 54:582-586.
75. Stamminger, T., Gstaiger, M., Weinzierl, K., Lorz, K., Winkler, M. and Schaffner, W., 2002, Open reading frame UL26 of human cytomegalovirus encodes a novel tegument protein that contains a strong transcriptional activation domain. J. Virol. 76:4836-4847.
76. Sullivan, V., Talarico, C. L., Stanat, S C., Davis, M., Coen, D. M. and Biron, K. K., 1992, A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
77. Sundstrom, P., Juto, P., Wadell, G., Hallmans, G., Svenningsson, A., Nystrom, L., Dillner, J. and Forsgren, L., 2004, An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62:2277-2282.
78. Taber, D. J., Ashcraft, E., Baillie, G. M., Berkman, S., Rogers, J., Baliga, P. K., Rajagopalan, P. R., Lin, A., Emovon, O., Afzal, F., and Chavin, K. D. 2004. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl. Infect. Dis. 6, 101-109.
79. Talarico, C. L., Burnette, T. C., Miller, W. H., Smith, S. L., Davis, M. G., Stanat, S. C., Ng, T. I., He, Z., Coen, D. M., Roizman, B. and Biron, K. K., 1999, Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Chemother. 43:1941-1946.
80. Thorley-Lawson, D. A., 2001, Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:75-82.
81. Thorley-Lawson, D. A. and Gross, A., 2004, Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350:1328-1337.
82. Townsend, L. B., Devivar, R. V., Turk, S. R., Nassiri, M. R. and Drach, J. C., 1995, Design, synthesis, and antiviral activity of certain 2, 5, 6-trihalo-1-(beta-D-ribofuranosyl) benzimidazoles. J. Med. Chem. 38:4098-4105.
83. Townsend, L. B., Gudmundsson, K. S., Daluge, S. M., Chen, J. J., Zhu, Z., Koszalka, G. W., Boyd, L., Chamberlain, S. D., Freeman, G. A., Biron, K. K. and Drach, J. C., 1999, Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB. Nucleosides Nucleotides 18:509-519.
84. Townsend, L. B. and Revankar, G. R., 1970, Benzimidazole nucleosides, nucleotides, and related derivatives. Chem. Rev. 70:389-438.
85. Underwood, M. R., Ferris, R. G., Selleseth, D. W., Davis, M. G., Drach, J. C., Townsend, L. B., Biron, K. K. and Boyd, F. L., 2004, Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob. Agents Chemother. 48:1647-1651.
86. Underwood, M. R., Harvey, R. J., Stanat, S. C., Hemphill, M. L., Miller, T., Drach, J. C., Townsend, L. B. and Biron, K. K., 1998, Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
87. Valantine, H. A., 2004, The role of viruses in cardiac allograft vasculopathy. Am. J. Transplant. 4:169-177.
88. Van Zeijl, M., Fairhurst, J., Baum, E. Z., Sun, L. and Jones, T. R., 1997, The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. Virology 231:72-80.
89. Vancikova, Z. and Dvorak, P., 2001, Cytomegalovirus infection in immunocompetent and immunocompromised i ndividuals-a review Curr. Drug Targets. Immune. Endocr. Metabol. Disord. 1:179-187.
90. Walling, D. M., Flaitz, C. M. and Nichols, C. M., 2003, Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J. Infect. Dis. 188:883-890.
91. Wang, L. H., Peck, R. W., Yin, Y., Allanson, J., Wiggs, R., and Wire, M. B., 2003, Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47:1334-1342.
92. Weiland, K. L., Oien, N. L., Homa, F. and Wathen, M. W., 1994, Functional analysis of human cytomegalovirus polymerase accessory protein. Virus Res 34:191-206.
93. Whitley, R. J., 2004, Congenital cytomegalovirus infection: epidemiology and treatment. Adv. Exp. Med. Biol. 549:155-160.
94. Williams, S. L., Hartline, C. B., Kushner, N. L., Harden, E. A., Bidanset, D. J., Drach, J. C., Townsend, L. B., Underwood, M. R., Biron, K. K. and Kern, E. R., 2003, In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186-2192.
95. Wolf, D. G., Courcelle, C. T., Prichard, M. N. and Mocarski, E. S., 2001, Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. U. S. A 98:1895-1900.
96. Yamazaki, M., Kitamura, R., Kusano, S., Eda, H., Sato, S., Okawa-Takatsuji, M., Aotsuka, S. and Yanagi, K., 2005, Elevated immunoglobulin G antibodies to the proline-rich aminoterminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjogren's syndrome patients with pulmonary involvements. Clin. Exp. Immunol. 139:558-568.
97. Yankulov, K., Yamashita, K., Roy, R., Egly, J. M., and Bentley, D L., 1995, The transcriptional elongation inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J. Biol. Chem. 270:23922-23925.
98. Zacny, V. L., Gershburg, E., Davis, M. G., Biron, K. K. and Pagano, J. S., 1999, Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J. Virol. 73:7271-7277.